Brief: Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026
30/09/2026 23:35
BRIEF-Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026 Oct 1 (Reuters) - BioMarin Pharmaceutical Inc. BMRN.O:
BIOMARIN PHARMACEUTICAL - ENTERS SETTLEMENT AND LICENSE AGREEMENT WITH ASCENDIS PHARMA ON SEPT 24, 2026 - SEC FILING
BIOMARIN PHARMACEUTICAL - GRANTS ASCENDIS LICENSE FOR TRANSCON CNP, NAVEPEGRITIDE, YUVIWEL - SEC FILING
BIOMARIN PHARMACEUTICAL - ASCENDIS TO PAY BIOMARIN 20% US, 18% EU/BR/SK ROYALTY ON SALES UNTIL MAY 2030 - SEC FILING
BIOMARIN PHARMACEUTICAL - CO AND ASCENDIS TO DISMISS ALL PENDING LITIGATION WITH PREJUDICE - SEC FILING
Further company coverage: BMRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioMarin Pharmaceutical
See all newsUS RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Brief: Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense
Brief: Biomarin Appoints Cara Bauer As Chief People Officer
Brief: Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026
U.S. STOCKS ON THE MOVE-GitLab, California utilities, Herbalife